Scarica l'app Stockscreener
9.41
13.51%
1.12
Dopo l'orario di chiusura:
9.59
0.18
+1.91%
Precedente Chiudi:
$8.29
Aprire:
$8.23
Volume 24 ore:
885.86K
Relative Volume:
5.62
Capitalizzazione di mercato:
$227.59M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+33.85%
1M Prestazione:
+28.11%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$7.925
$9.51
Intervallo di 1 settimana:
$6.565
$9.51
Portata 52W:
$6.565
$13.47
Jade Biosciences Inc Stock (JBIO) Company Profile
Nome
Jade Biosciences Inc
Settore
Industria
Telefono
617-443-2400
Indirizzo
930 WINTER STREET, WALTHAM
Confronta JBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
9.41 | 227.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-05-07 | Iniziato | Wedbush | Outperform |
| 2025-05-05 | Iniziato | Stifel | Buy |
| 2025-05-02 | Iniziato | TD Cowen | Buy |
| 2024-06-18 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-06-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-03-25 | Ripresa | Jefferies | Buy |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-12-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-08-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-07-26 | Iniziato | Cowen | Outperform |
| 2021-07-26 | Iniziato | Evercore ISI | Outperform |
| 2021-07-26 | Iniziato | Jefferies | Buy |
| 2021-07-26 | Iniziato | Wedbush | Outperform |
Mostra tutto
Jade Biosciences Inc Borsa (JBIO) Ultime notizie
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - marketscreener.com
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
JADE-101 ameliorates IgA nephropathy features in preclinical setting - BioWorld MedTech
Jade Biosciences Presents JADE101 Preclinical Data at the - GlobeNewswire
New IgA Nephropathy Drug Shows 750x Better Binding: JADE101 Outperforms Competitors in Key Metrics - Stock Titan
Jade Biosciences Announces Presentation of Preclinical Data on JADE101 at 62nd European Renal Association Congress - Nasdaq
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress - GlobeNewswire
Breakthrough IgA Nephropathy Treatment: Jade Biosciences Reveals New JADE101 Antibody Data at ERA Congress - Stock Titan
Insider Buying: CEO Tom Frohlich Acquires Shares in Jade Bioscie - GuruFocus
JBIOJade Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences, Inc. Completes Reverse Merger, Launches Nasdaq Trading as JBIO, and Secures $300 Million Financing - Nasdaq
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target By Investing.com - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating By Investing.com - Investing.com Nigeria
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
JBIO Stock Price and Chart — NASDAQ:JBIO - TradingView
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics (AVTE) Declares Special Dividend Amid Merg - GuruFocus
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Aerovate Therapeutics Inc. (AVTE) reports earnings - qz.com
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders - The Malaysian Reserve
Jade Biosciences to Participate in TD Cowen’s 45th Annual - GlobeNewswire
Jade Biosciences, Inc. to Present New Preclinical Data on Jade101 At the 62nd European Renal Association Congress - marketscreener.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerIPG, VTS, AVTE, MHLD - The Victoria Advocate
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire
Jade Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
How Fairmount’s Paragon incubator steered two more companies to NASDAQ - BioCentury
Paragon spinout Jade casts reverse merger spell with Aerovate - Fierce Biotech
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger - Endpoints News
Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson - Endpoints News
Jade Biosciences Inc Azioni (JBIO) Dati Finanziari
Non sono disponibili dati finanziari per Jade Biosciences Inc (JBIO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):